Congratulations to Syntrix scientists on their latest issued patents at the United States Patent and Trademark Office. ‘701 Abstract: Disclosed herein is a composition for oral administration of O-desmethyltramadol that is effective for overcoming resistance to tramadol in patients. ‘700 and ‘432 Abstracts: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.
